Activin and Inhibin

DCLX069 is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC 50 value of 17.9 µM. DCLX069 shows less active against PRMT4 and PRMT6 . DCLX069 has anticancer effectsIn VitroDCLX069 (12.5-100 µM) effectively blocks cell

DCLX069 is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC 50 value of 17.9 µM. DCLX069 shows less active against PRMT4 and PRMT6 . DCLX069 has anticancer effectsIn VitroDCLX069 (12.5-100 µM) effectively blocks cell

DCLX069 is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC 50 value of 17.9 µM. DCLX069 shows less active against PRMT4 and PRMT6 . DCLX069 has anticancer effectsIn VitroDCLX069 (12.5-100 µM) effectively blocks cell

DCLX069 is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC 50 value of 17.9 µM. DCLX069 shows less active against PRMT4 and PRMT6 . DCLX069 has anticancer effectsIn VitroDCLX069 (12.5-100 µM) effectively blocks cell

DCLX069 is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC 50 value of 17.9 µM. DCLX069 shows less active against PRMT4 and PRMT6 . DCLX069 has anticancer effectsIn VitroDCLX069 (12.5-100 µM) effectively blocks cell

DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patientsIn VitroDCZ0415 (10,

DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patientsIn VitroDCZ0415 (10,

DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patientsIn VitroDCZ0415 (10,

DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patientsIn VitroDCZ0415 (10,

DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patientsIn VitroDCZ0415 (10,

ddCTP trisodium is one of 2',3'-dideoxyribonucleoside 5'-triphosphates (ddNTPs) that acts as chain-elongating inhibitor of DNA polymerase for DNA sequencing. ddCTP trisodium is a nucleoside analog that targets the reverse transcriptase of human

ddGTP (2′,3′-Dideoxyguanosine 5′-triphosphate) trisodium is one of 2',3'-dideoxyribonucleoside 5'-triphosphates (ddNTPs) that acts as chain-elongating inhibitor of DNA polymerase for DNA sequencing. ddGTP trisodium acts as an inhibitor or a